The effect of 15(R)-15-methyl prostaglandin E2 on meal-stimulated gastric acid secretion, serum gastrin, and pancreatic polypeptide in duodenal ulcer patients

Walter Peterson, Mark Feldman, Ian Taylor, Michael Bremer

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The effects of 100-μg doses of 15(R)-15-methyl prostaglandin E2 on meal-stimulated acid secretion, serum gastrin, and pancreatic polypeptide concentrations were measured in patients with duodenal ulcer. The drug given in encapsulated or unencapsulated form significantly reduced gastric acid secretion by 59% or 70%, respectively. Rises in serum gastrin and pancreatic polypeptide concentrations after the meal were significantly blunted by 15(R)-15-methyl prostaglandin E2. This dose of prostaglandin led to no side effects and merits clinical evaluation in the treatment of peptic ulcer disease.

Original languageEnglish (US)
Pages (from-to)381-384
Number of pages4
JournalDigestive Diseases and Sciences
Volume24
Issue number5
DOIs
StatePublished - May 1979

Fingerprint

Pancreatic Polypeptide
Gastric Acid
Gastrins
Duodenal Ulcer
Dinoprostone
Meals
Serum
Peptic Ulcer
Prostaglandins
Acids
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Gastroenterology

Cite this

The effect of 15(R)-15-methyl prostaglandin E2 on meal-stimulated gastric acid secretion, serum gastrin, and pancreatic polypeptide in duodenal ulcer patients. / Peterson, Walter; Feldman, Mark; Taylor, Ian; Bremer, Michael.

In: Digestive Diseases and Sciences, Vol. 24, No. 5, 05.1979, p. 381-384.

Research output: Contribution to journalArticle

@article{1f9cc291b9dc4951bf82bb6cabcc69e6,
title = "The effect of 15(R)-15-methyl prostaglandin E2 on meal-stimulated gastric acid secretion, serum gastrin, and pancreatic polypeptide in duodenal ulcer patients",
abstract = "The effects of 100-μg doses of 15(R)-15-methyl prostaglandin E2 on meal-stimulated acid secretion, serum gastrin, and pancreatic polypeptide concentrations were measured in patients with duodenal ulcer. The drug given in encapsulated or unencapsulated form significantly reduced gastric acid secretion by 59{\%} or 70{\%}, respectively. Rises in serum gastrin and pancreatic polypeptide concentrations after the meal were significantly blunted by 15(R)-15-methyl prostaglandin E2. This dose of prostaglandin led to no side effects and merits clinical evaluation in the treatment of peptic ulcer disease.",
author = "Walter Peterson and Mark Feldman and Ian Taylor and Michael Bremer",
year = "1979",
month = "5",
doi = "10.1007/BF01297125",
language = "English (US)",
volume = "24",
pages = "381--384",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "5",

}

TY - JOUR

T1 - The effect of 15(R)-15-methyl prostaglandin E2 on meal-stimulated gastric acid secretion, serum gastrin, and pancreatic polypeptide in duodenal ulcer patients

AU - Peterson, Walter

AU - Feldman, Mark

AU - Taylor, Ian

AU - Bremer, Michael

PY - 1979/5

Y1 - 1979/5

N2 - The effects of 100-μg doses of 15(R)-15-methyl prostaglandin E2 on meal-stimulated acid secretion, serum gastrin, and pancreatic polypeptide concentrations were measured in patients with duodenal ulcer. The drug given in encapsulated or unencapsulated form significantly reduced gastric acid secretion by 59% or 70%, respectively. Rises in serum gastrin and pancreatic polypeptide concentrations after the meal were significantly blunted by 15(R)-15-methyl prostaglandin E2. This dose of prostaglandin led to no side effects and merits clinical evaluation in the treatment of peptic ulcer disease.

AB - The effects of 100-μg doses of 15(R)-15-methyl prostaglandin E2 on meal-stimulated acid secretion, serum gastrin, and pancreatic polypeptide concentrations were measured in patients with duodenal ulcer. The drug given in encapsulated or unencapsulated form significantly reduced gastric acid secretion by 59% or 70%, respectively. Rises in serum gastrin and pancreatic polypeptide concentrations after the meal were significantly blunted by 15(R)-15-methyl prostaglandin E2. This dose of prostaglandin led to no side effects and merits clinical evaluation in the treatment of peptic ulcer disease.

UR - http://www.scopus.com/inward/record.url?scp=0018396622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018396622&partnerID=8YFLogxK

U2 - 10.1007/BF01297125

DO - 10.1007/BF01297125

M3 - Article

C2 - 456224

AN - SCOPUS:0018396622

VL - 24

SP - 381

EP - 384

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 5

ER -